SAN DIEGO , Feb. 15, 2025 /PRNewswire/ -- The law firm ofRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period"), have until April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit.  Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics and certain of TransMedics' top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the TransMedics class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-transmedics-group-inc-class-action-lawsuit-tmdx.html  

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.

CASE ALLEGATIONS: TransMedics is a commercial-stage medical technology company that engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

The TransMedics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (ii) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (iii) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk.

The TransMedics class action lawsuit further alleges that on February 21, 2024, U.S. Representative Paul Gosar issued a letter accusing TransMedics of misconduct including misappropriating corporate resources and the letter was reported on by The Daily Caller during market hours on February 22, 2024.  On this news, the price of TransMedics stock fell, according to the complaint.

Then, the TransMedics class action lawsuit also alleges that on January 10, 2025, Scorpion Capital issued a report accusing TransMedics of, among other things, overbilling hospitals that use its services, effectively forcing customers to use certain services, and providing to patients organs that had been rejected by reputable physicians, by way of physicians who were paid by TransMedics.  On this news, the price of TransMedics stock fell further, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired TransMedics publicly traded securities during the Class Period to seek appointment as lead plaintiff in the TransMedics class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the TransMedics class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the TransMedics class action lawsuit.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the TransMedics class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases.  Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors.  We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tmdx-investor-alert-transmedics-group-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302377475.html

SOURCE Robbins Geller Rudman & Dowd LLP